ライフサイエンスコーパス: obliterative

1 polymorphic H13 allele in the development of obliterative airway disease (OAD) after murine heterotop

2 A model for obliterative airway disease (OAD) after tracheal allogra

3 tant role in the development of experimental obliterative airway disease (OAD) after transplantation.

4 er KCa3.1 contributes to the pathogenesis of obliterative airway disease (OAD) and whether knockout o

5 ty of this mAb to prevent the development of obliterative airway disease (OAD) in murine recipients o

6 d whether epithelial re-growth could prevent obliterative airway disease (OAD) in orthotopic tracheal

7 nsplanted allogeneic murine tracheas develop obliterative airway disease (OAD) leading to a lesion re

8 by the recipient CD4(+) T cells to show that obliterative airway disease (OAD) that developed in thes

9 formed in a murine model of anti-MHC-induced obliterative airway disease (OAD), a correlate of oblite

10 cally transplanted allograft airways develop obliterative airway disease (OAD), an immunologically me

11 Using a murine model of obliterative airway disease (OAD), we recently demonstra

12 lly allogeneic mismatched recipients develop obliterative airway disease (OAD), which is a suitable m

13 examined the role airway epithelium plays in obliterative airway disease (OAD).

14 system in the pathogenesis of posttransplant obliterative airway disease (OAD).

15 experimental obliterative bronchiolitis [ie, obliterative airway disease (OAD)] in rat tracheal allog

16 brosis and obstruction of the small airways (obliterative airway disease [OAD]) mediated predominantl

17 In untreated rats, marked obliterative airway disease developed over 60 days.

18 cts of rapamycin (RPM) on the development of obliterative airway disease in murine recipients of hete

19 osuppresive compounds to prevent and reverse obliterative airway disease in these animals.

20 e Janus kinase 1/3 inhibitor R507 to prevent obliterative airway disease was analyzed in preclinical

21 immunosuppressant that similarly diminished obliterative airway disease with systemic or inhaled adm

22 and Collagen-V leading to the development of obliterative airway lesions (OAD), correlate of chronic

23 This obliterative airways disease (OAD) also develops in hete

24 irway tissue secondary to the development of obliterative airways disease.

25 , intima proliferation, and various forms of obliterative and plexiform-like lesions in pulmonary art

26 s the morphologic features of the acute vaso-obliterative and vasoproliferative stages of oxygen-indu

27 rejection is manifested in this BM group by obliterative arteriopathy and the epicardium and endocar

28 Two resected specimens showed obliterative arteriopathy indicative of chronic rejectio

29 is unique murine model of PAH-like plexiform/obliterative arteriopathy induced via a two-hit pathophy

30 on (PAH) that recapitulate the plexiform and obliterative arteriopathy seen in PAH patients and help

31 llograft inflammation and the development of obliterative arteriopathy.

32 immunological injury and the development of obliterative arteriopathy.

33 in an animal model of chronic rejection and obliterative arteriopathy.

34 resence of infectious organisms, transplant (obliterative) arteriopathy, neoplasia, relative proporti

35 Obliterative bronchiolitis (OB) after lung transplantati

36 id into the lung mediates the development of obliterative bronchiolitis (OB) in orthotopic WKY-to-F34

37 Obliterative bronchiolitis (OB) is a clinical syndrome m

38 Obliterative bronchiolitis (OB) is a devastating complic

39 Obliterative bronchiolitis (OB) is a dreaded and frequen

40 Obliterative bronchiolitis (OB) is the histopathological

41 Obliterative bronchiolitis (OB) is the most serious late

42 Obliterative bronchiolitis (OB) is the primary cause of

43 Obliterative bronchiolitis (OB) post-lung transplantatio

44 Chronic allograft rejection manifested as obliterative bronchiolitis (OB) remains the single great

45 Actuarial probability of remaining free from obliterative bronchiolitis (OB)* tended to be higher in

46 Obliterative bronchiolitis (OB), an important threat to

47 syndrome and its histopathologic correlate, obliterative bronchiolitis (OB), are a major source of m

48 n bronchoalveolar lavage (BAL) had developed obliterative bronchiolitis (OB), but only 8 of the 38 su

49 Lung transplant survival is limited by obliterative bronchiolitis (OB), but the mechanisms of O

50 mmation, lymphocytic bronchiolitis (LB), and obliterative bronchiolitis (OB), causes substantial morb

51 Obliterative bronchiolitis (OB), chronic allograft rejec

52 Chronic lung allograft rejection, known as obliterative bronchiolitis (OB), is the leading cause of

53 Obliterative bronchiolitis (OB), or chronic allograft re

54 changed); both parameters correlated with an obliterative bronchiolitis (OB)-free state.

55 isk factor for the subsequent development of obliterative bronchiolitis (OB).

56 ognized small-airway histological process of obliterative bronchiolitis (OB).

57 ut survival is limited by the development of obliterative bronchiolitis (OB).

58 ion, epithelial damage, and eventual luminal obliterative bronchiolitis (OB).

59 afts develop chronic rejection manifested as obliterative bronchiolitis (OB).

60 ajor histological features of posttransplant obliterative bronchiolitis (OB).

61 iogenesis during development of experimental obliterative bronchiolitis [ie, obliterative airway dise

62 ection, manifested as small airway fibrosis (obliterative bronchiolitis [OB]), is the main obstacle t

63 Obliterative bronchiolitis after lung transplantation is

64 The etiology and pathogenesis of obliterative bronchiolitis after lung transplantation re

65 ulate T-cell responses in the development of obliterative bronchiolitis after lung transplantation.

66 geneic immune response in the development of obliterative bronchiolitis after lung transplantation.

67 e critical role of T cells in development of obliterative bronchiolitis among human lung allograft re

68 s treated with CMVIG had lower incidences of obliterative bronchiolitis and death from obliterative b

69 of obliterative bronchiolitis and death from obliterative bronchiolitis and longer survival compared

70 Nine patients with histologic active obliterative bronchiolitis and progressively worsening a

71 In this study, we induced obliterative bronchiolitis and studied the contribution

72 cessive amount of NO promotes posttransplant obliterative bronchiolitis by destroying airway epitheli

73 tes to the development of lung rejection and obliterative bronchiolitis by mediating effector T lymph

74 (angiographic); and incidence and death from obliterative bronchiolitis defined by pathological crite

75 logical lesions similar to those typical for obliterative bronchiolitis developed in vivo after recon

76 ith cyclosporine, in preventing and treating obliterative bronchiolitis in heart-lung and lung allogr

77 hymal cells, which is a lesion comparable to obliterative bronchiolitis in human lung transplant reci

78 n with histologic features characteristic of obliterative bronchiolitis in human lung transplant reci

79 ubtypes all contribute to the development of obliterative bronchiolitis in the heterotopic mouse trac

80 Obliterative bronchiolitis is a frequent, morbid, and us

81 Obliterative bronchiolitis is the major cause of long-te

82 ication of lung transplantation, may promote obliterative bronchiolitis leading to graft failure in l

83 Efforts to reduce the development of obliterative bronchiolitis may require the antagonism of

84 ose of this study was to investigate whether obliterative bronchiolitis might occur after xenogenic p

85 o develop a murine chimera model that mimics obliterative bronchiolitis of lung allograft recipients

86 Obliterative bronchiolitis remains a major long-term com

87 assified as stable (DL-S, n = 11), or having obliterative bronchiolitis syndrome (DL-OBS, n = 4).

88 because of chronic rejection in the form of obliterative bronchiolitis syndrome (OBS).

89 Mechanistic study of obliterative bronchiolitis would be aided by development

90 isorders include constrictive bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), a

91 nifestations of chronic rejection, including obliterative bronchiolitis, interstitial fibrosis, and o

92 Chronic inflammation, a hallmark of obliterative bronchiolitis, is known to induce lymphangi

93 ET-1 expression did not vary with rejection, obliterative bronchiolitis, or infection.

94 These data show that in this murine model of obliterative bronchiolitis, these chemokines are differe

95 tatins during postoperative Year 1 developed obliterative bronchiolitis, whereas the cumulative incid

96 y of HO-1 accelerates the development of the obliterative bronchiolitis-like lesion.

97 tology to study the airway injury related to obliterative bronchiolitis.

98 ave value in the prevention and treatment of obliterative bronchiolitis.

99 gainst the mesenchymal cell proliferation of obliterative bronchiolitis.

100 afts develop chronic rejection manifested as obliterative bronchiolitis.

101 baseline) and/or the presence of histologic obliterative bronchiolitis.

102 e (OAD) leading to a lesion resembling human obliterative bronchiolitis.

103 etely effective therapy for the treatment of obliterative bronchiolitis.

104 erative airway disease (OAD), a correlate of obliterative bronchiolitis.

105 to the small human airway grafts, and caused obliterative bronchiolitis.

106 rlying another chronic inflammatory disease, obliterative bronchiolitis.

107 tion-associated chronic complications, e.g., obliterative bronchiolitis.

108 s isolated from the airways of patients with obliterative bronchiolitis.

109 ine heterotopic tracheal allograft model for obliterative bronchiolitis.

110 mplicated in late graft failure secondary to obliterative bronchiolitis.

111 s in the mouse heterotopic tracheal model of obliterative bronchiolitis.

112 tic cells (DC) is thought to be important in obliterative bronchiolitis/bronchiolitis obliterans synd

113 characterized by the pathologic findings of obliterative bronchiolitis: neutrophil influx and extrac

114 -treated kidneys had more extensive arterial obliterative changes and glomerulosclerosis after 24 wee

115 Elafin reverses obliterative changes in pulmonary arteries via elastase

116 Biliary atresia is an obliterative cholangiopathy of infancy that is fatal if

117 an unusually accelerated and diffuse form of obliterative coronary arteriosclerosis, determines long-

118 is obliterans (BO), a common and devastating obliterative disorder of small airways following lung tr

119 t the cause is probably multifactorial, with obliterative extrahepatic cholangiopathy as the common e

120 could cause biliary atresia, an idiopathic, obliterative infantile disease of bile ducts that is the

121 Based on the fibro-obliterative lesion found during bronchiolitis obliteran

122 uman patients, induce formation of plexiform/obliterative lesions and defined the molecular mechanism

123 esions occur as solitary lesions, concentric-obliterative lesions appear to be only associated with,

124 in an attempt to treat established vascular-obliterative lung disease.

125 Forty-four patients with chronic obliterative main PVT were identified during our institu

126 trate that plexiform (n = 14) and concentric-obliterative (n = 6) lesions occur distal to branch poin

127 bliterans syndrome (BOS), a process of fibro-obliterative occlusion of the small airways in the trans

128 TRAIL does not play a major role in the vaso-obliterative phase of oxygen-induced retinopathy.

129 Tumorous swelling, eosinophilia, and obliterative phlebitis are other frequently observed fea

130 by tumefactive lesions, storiform fibrosis, obliterative phlebitis, and accumulation of IgG4-express

131 of IgG4(+) plasma cells, storiform fibrosis, obliterative phlebitis, and mild to moderate eosinophili

132 f IgG4(+) plasma cells, tumefactive lesions, obliterative phlebitis, and mild to moderate eosinophili

133 acytic infiltration, storiform fibrosis, and obliterative phlebitis.

134 sitive plasma cells, storiform fibrosis, and obliterative phlebitis.

135 sociated with germinal centers, fibrosis and obliterative phlebitis.

136 pancreatic ducts and ductules, combined with obliterative phlebitis.

137 Chronic, obliterative portal vein (PV) thrombosis (PVT) represent

138 ed and sexual function is no longer desired, obliterative procedures, which are better tolerated, may

139 Biliary atresia, a progressive obliterative process involving the bile ducts, has its o

140 Graft arterial disease (GAD) is a vascular obliterative process mediated via the Th1 cytokine inter

141 mune system activation with autoimmunity; an obliterative, proliferative small vessel vasculopathy; a

142 apies for the treatment of asthma or chronic obliterative pulmonary disease.

143 PVR-TIPS may be considered for patients with obliterative PVT who are otherwise appropriate candidate

144 after lung transplantation is bronchiolitis obliterative syndrome (BOS).

145 be categorised broadly by reconstructive and obliterative techniques.

146 d inflammation are mechanistically linked to obliterative tissue fibrosis.

147 ial amount of smooth muscle cells within the obliterative tissue was of donor origin.

148 Wnt-betaC and Wnt-PCP pathways contribute to obliterative vascular disease in both the systemic and p

149 tics observed in patients with PAH and other obliterative vascular diseases.

150 first genetically modified mouse model with obliterative vascular remodeling and pathophysiology rec

151 ts indicate that LG3 is a novel regulator of obliterative vascular remodeling during rejection.

152 However, the mechanisms of obliterative vascular remodeling remain elusive; hence,

153 onset of chronic rejection characterized by obliterative vasculopathy and the rejection of secondary

154 e connective tissue disease characterized by obliterative vasculopathy and tissue fibrosis.

155 temic sclerosis involves a proliferative and obliterative vasculopathy resulting from endothelial cel

156 rying degrees of skin and organ fibrosis and obliterative vasculopathy.